Cardiologist Dr. Anish Koka weighs in: “This should hopefully end the mainstream expert narrative of characterizing vaccine myocarditis as mild.”
The academic publication in the European Heart Journal can be found here.New South Korean Study Identifies High Rate of Severe Myocarditis Cases
A new South Korean nationwide study on vaccine-related myocarditis contains troubling implications on the severity of cardiac damage conferred by the mass experiment conducted on the population—young men in particular—without informed consent and a clear understanding of risk-reward ratios.
This new study published in the European Heart Journal is incredibly comprehensive. In South Korea, the Korean Disease Control and Prevention Agency (KDCA) established a reporting system to make it legally obligatory to report vaccine adverse events such as myocarditis.
Among 44,276,704 South Koreans vaccinated, 1,533 cases of suspected myocarditis were identified under the KDCA. Of the 1,533 total cases, the KDCA’s “Expert Adjudication Committee on COVID-19 Vaccination Pericarditis/Myocarditis” confirmed 480 cases. The population-wide risk comes to 1 in 100,000.
Most importantly, of the vaccinated South Korean population in the study, less than three-quarters took the mRNA jabs (71 percent), of which 56 percent took the Pfizer shots. Only 15 percent of vaccinees took the Moderna shots. This is noteworthy because vaccine-induced myocarditis incidence is far higher in those vaccinated with the Moderna product. The same link has not been robustly identified in non-mRNA COVID-19 vaccines. Almost a third of vaccinated South Koreans took a non-mRNA vaccine (AstraZeneca and the Johnson & Johnson vaccine).
Secondly, the study did not tally myocarditis rates by vaccine dose for different age groups in men and women. The second dose of the vaccine is known to cause higher rates of myocarditis in young men than the first. In other words, a more careful breakdown by dose and vaccine type would have revealed a far higher incidence of vaccine myocarditis. The researchers did, however, compare myocarditis incidence across vaccine doses broadly (without breaking it down by age and gender, as mentioned):
Predictably, Moderna dose two is associated with the highest rate of 1 in 86,000. Pfizer is the second most dangerous vaccine in this regard, with an incidence of 1 in 166,600 per vaccinated persons after the second dose. Comparatively, the AstraZeneca vaccine is associated with a 1 in 1,111,111 incidence of vaccine-related myocarditis.
Unsurprisingly, this study shows the mRNAs are far more dangerous (at least on the myocarditis front) than other COVID-19 vaccines.
As Koka further explained, “The committee rejected the level 3 BC case definition of myocarditis and the level 2 BC case definition that did not have associated cardiac damage evident on a blood test or any case with a positive result for COVID-19 infection.” As a result, many probable and likely cases of vaccine myocarditis were excluded due to highly stringent criteria.
Koka views a 20 percent rate of serious complications from vaccine-related myocarditis as “startling.”
“This should hopefully end the mainstream expert narrative of characterizing vaccine myocarditis as mild,” he added.
Again, if researchers controlled for the mRNA vaccine and dose two specifically in young men, what would the rate of severe myocarditis have been? This question remains unanswered.
“21 deaths, all in those aged 45 or less, were ultimately attributed to the vaccine. 8 of these deaths were sudden cardiac arrests that were diagnosed with myocarditis on autopsy because the Korean vaccine compensation program requires autopsies on patients that die after vaccination.
A rigorous cost-benefit analysis was never done—and could not have initially been done with such vast uncertainty and moving variables in the spring of 2021 when vaccines were widely distributed.
Now, it is increasingly clear how wrong mRNA vaccine enforcers were.
“This data makes it very difficult to understand the rationale for vaccinating young healthy individuals in 2023 who appear to be at vanishingly small risk of severe COVID. As any physician in the US who spends any time in hospitals over the last few years will tell you, hospitalization[s] for severe COVID are exceedingly rare.
